Javelin Pharma: Late-Stage Pipeline Targets Pain Print E-mail
Sunday, 15 March 2009 17:10

Javelin Pharma (JAV) is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject (injectable diclofenac) with Therabel Pharma to market the drug in Europe, where it is already approved for use.

The deal is worth up to $71M (with $12M in upfront cash and investor relation services from various entities and


128183000:2016-05-01 02:50:27 firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
blog comments powered by Disqus


BioMedReports Q BioMed's CEO featured in article he wrote titled Accelerators Enter When VCs Fear To Tread: https://t.co/NuOXexgSaY $QBIO
BioMedReports DiaMedica Completes Issue of Shares for Debt to BFC Group: https://t.co/PbNeO3NBAF $DMCAF
BioMedReports AstraZeneca Beefs Up Immuno-Oncology Pipeline with TapImmune Technology: https://t.co/zvvP1grhgr $TPIV